Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Premium Services
Financial News
Latest
Earnings
Guidance
Dividends
M&A
Buybacks
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Small-Cap
Markets
Pre-Market
After Hours
Movers
ETFs
Options
Cryptocurrency
Commodities
Bonds
Futures
Mining
Real Estate
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Investing Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
Analyst Ratings
Analyst Color
Latest Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Unusual Options Activity Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Compare Best Stocks

Best Momentum Stocks

Best Quality Stocks

Best Value Stocks

Best Growth Stocks

Comments

Loading...

Molecular Partners Stock News

MLLCFOTCPK

Logo brought to you by Benzinga Data

Trade with Public

Trade with Public

$4.05

0.051.25%

Last update: Dec 16, 9:30 AM

News

Latest Molecular Partners Stock News | OTC:MLLCF | Benzinga

Get the latest news on Molecular Partners stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Molecular Partners performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, August 09, 2021

AbbVie Returns Eye Drug Candidate To Molecular Partners
Vandana Singh

Tuesday, July 13, 2021

Cowen Initiates Coverage On Molecular Partners With Price Target Of $50
Vandana Singh

Thursday, July 08, 2021

Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant
Vandana Singh

Thursday, July 01, 2021

Novartis Looks To Enter mRNA Technology, Says Chairman: Reuters
Vandana Singh

Thursday, May 27, 2021

The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Shanthi Rexaline
Novartis, Molecular Partners Initiate Global Trial For COVID-19 Treatment
Vandana Singh

Tuesday, March 09, 2021

Molecular Partners/Novartis's COVID-19 Antiviral Therapy Shows Encouraging Action Early-Stage Study
Vandana Singh

Wednesday, October 28, 2020

Molecular Partners Announced Collaboration with Novartis to Develop two DARPin Therapies Designed for Potential Use against COVID-19
Charles Gross
Novartis Strikes Deal To Commercialize Molecular Partners' COVID-19 Drug Candidates
Shivdeep Dhaliwal

Friday, June 26, 2020

AbbVie Company Allergan and Molecular Partners Receive CRL from FDA on Biologics License Application for Abicipar pegol
Charles Gross

Friday, October 04, 2019

Allergan Partner Molecular Partners Announces Late-Stage Data from Abicipar in Age-Related Macular Degeneration to be Showcased at American Academy of Ophthalmology (AAO) Annual Meeting
Charles Gross

Wednesday, December 19, 2018

Amgen, Molecular Partners Announce Strategic Collaboration In Immuno-Oncology; Molecular Partners to Receive $50M Upfront; Up to $497M in Milestones
Charles Gross

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved